MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM)

被引：0

作者：

Walker, Christopher ^{[1
]}

Shen, Yao ^{[2
]}

Mau-Soerensen, Morten ^{[3
]}

Wen, Patrick ^{[4
]}

van den Bent, Martin ^{[5
]}

Plotkin, Scott ^{[6
]}

Walenkamp, Annemiek ^{[7
]}

Green, Adam ^{[8
]}

Califano, Andrea ^{[2
]}

Chang, Hua ^{[1
]}

Tamir, Sharon ^{[1
]}

Henegar, Leah ^{[1
]}

Shacham, Sharon ^{[1
]}

Alvarez, Mariano ^{[2
]}

Landesman, Yosef ^{[1
]}

Lassman, Andrew ^{[9
]}

机构：

[1] Karyopharm Therapeut Inc, Newton, MA USA

[2] Darwin Hlth, New York, NY USA

[3] Rigshosp, Copenhagen Univ Hosp, Copenhagen, Denmark

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Erasmus MC Canc Inst, Rotterdam, Netherlands

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Univ Groningen, Groningen, Netherlands

[8] Univ Colorado, Aurora, CO USA

[9] Columbia Univ, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BIOM-26

引用

页码：7 / 7

页数：1

共 50 条

[21] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Kreisl, Teri N.
Lassman, Andrew B.
Mischel, Paul S.
Rosen, Neal
Scher, Howard I.
Teruya-Feldstein, Julie
Shaffer, David
Lis, Eric
Abrey, Lauren E.
JOURNAL OF NEURO-ONCOLOGY, 2009, 92 (01) : 99 - 105
[22] A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Teri N. Kreisl
Andrew B. Lassman
Paul S. Mischel
Neal Rosen
Howard I. Scher
Julie Teruya-Feldstein
David Shaffer
Eric Lis
Lauren E. Abrey
Journal of Neuro-Oncology, 2009, 92 : 99 - 105
[23] Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
Raval, S.
Hwang, S.
Dorsett, L.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[24] PRELIMINARY RESULTS OF A PHASE I/II TRIAL OF SELINEXOR AND TEMOZOLOMIDE IN RECURRENT GLIOBLASTOMA
Chow, Frances
Berens, Michael
Palmer, Joycelynne
Villalona-Calero, Miguel
Ney, Douglas
de la Fuente, Macarena
Jaeckle, Kurt
Kizilbash, Sani H.
Nasany, Ruham Alshiekh
Hrachova, Maya
Porter, Alyx B.
Piccioni, David
Hoang, Kimberly
Lipinski, Lindsay
Strowd, Roy
Giglio, Pierre
Mantica, Megan
Schiff, David
Gore, Steven
Portnow, Jana
NEURO-ONCOLOGY, 2024, 26
[25] INTERIM ANALYSIS DATA FROM PHASE 2 STUDY ON EFFICACY, SAFETY & INTRATUMORAL PHARMACOKINETICS OF ORAL SELINEXOR (KPT-330) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
Lassman, A. B.
Bent, M. J. V. D.
Wen, P. Y.
Walenkamp, A.
Plotkin, S.
Kung, A.
Gardner, H.
Shacham, S.
Chudnovsky, A.
Mau-Sorensen, P. M.
NEURO-ONCOLOGY, 2017, 19 : 14 - 14
[26] Visualizing Molecular Profiles of Glioblastoma with GBM-BioDP
Celiku, Orieta
Johnson, Seth
Zhao, Shuping
Camphausen, Kevin
Shankavaram, Uma
PLOS ONE, 2014, 9 (07):
[27] HISTOPATHOLOGIC RESPONSE CRITERIA FOLLOWING TREATMENT OF GLIOBLASTOMA (GBM)
Lassman, Andrew
Zanazzi, George
Bruce, Jeffrey
Englander, Zachary
Bowden, Stephen
Grinband, Jack
Chang, Peter
Lignelli, Angela
Canoll, Peter
NEURO-ONCOLOGY, 2017, 19 : 174 - 174
[28] Stereotactic radiosurgery (SRS) - Treatment option for recurrent glioblastoma multiforme (GBM)
Combs, SE
Widmer, V
Thilmann, C
Hof, H
Debus, J
Schulz-Ertner, D
CANCER, 2005, 104 (10) : 2168 - 2173
[29] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
Sathornsumetee, Sith
Vredenburgh, James
Rich, Jeremy
Desjardins, Annick
Quinn, Jennifer
Bota, Daniela
Goli, Krishna
Mathe, Alyssa
Gururangan, Sridharan
Friedman, Allan
Friedman, Henry
Reardon, David
NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
[30] Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy
Hatef Mehrabian
Sten Myrehaug
Hany Soliman
Arjun Sahgal
Greg J. Stanisz
Scientific Reports, 8

← 1 2 3 4 5 →